10 FAQs About Mirabilis: Pharmaceutical Impurity Control Using In Silico Tools

Identification and control of impurities in active pharmaceutical ingredients (APIs) and pharmaceutical drug products is critical in drug development. Mirabilis is our innovative solution designed to address this challenge. In this post, we’ll answer ten frequently asked questions about Mirabilis. What is Mirabilis? Mirabilis is an in silico tool developed by Lhasa Limited that […]

10 FAQs About Mirabilis: Pharmaceutical Impurity Control Using In Silico Tools Read More »

degradation and nitrosamine risk assessment webinar blog cover image

Did you miss our webinar on degradation chemistry and nitrosamine risk assessment? Here are 5 top takeaways!

Discuss / lara.james

If you couldn’t join us for our recent webinar, “Identifying the Formation of Nitrosamines via Degradation Pathways Using an In-Silico Approach,” we’ve got you covered! We explored how Zeneth, our cutting-edge software solution, can help you detect potential degradation issues early in the drug development workflow, specifically in the context of nitrosamine risk assessment. We

Did you miss our webinar on degradation chemistry and nitrosamine risk assessment? Here are 5 top takeaways! Read More »

Have you read this? Benchmarking In silico prediction of pharmaceutical degradation pathways

Discuss, Innovate / lara.james

We are delighted to share our important new open access article: In silico prediction of pharmaceutical degradation pathways: A benchmarking study using the software program Zeneth. The paper, recently published in Organic Process Research & Development (OPRD) is authored by Lhasa Principal Scientist Rachel Hemingway, alongside industry expert co-authors from AstraZeneca, GSK, Pfizer, BMS, Amgen

Have you read this? Benchmarking In silico prediction of pharmaceutical degradation pathways Read More »

Safeguarding Pharmaceutical Development: The Importance of Early Risk Mitigation

Innovate / lara.james

Ensuring the safety and efficacy of active pharmaceutical ingredients (APIs) is of paramount importance. A critical aspect of this process involves the identification and mitigation of potentially mutagenic impurities, like nitrosamines. In this blog, we will explore the significance of risk mitigation at the early stages of API development and introduce a cutting-edge solution, Zeneth,

Safeguarding Pharmaceutical Development: The Importance of Early Risk Mitigation Read More »

The importance of sharing knowledge for innovation

Life at Lhasa, Innovate / lara.james

“When you are innovating, ultimately it comes down to how that innovation is used by the end user… Where does the problem really lie before you dive in and propose a technology solution?” Peter Bannister, Technology Advisory Community Consultant at Endava. Here at Lhasa, we take this concept to heart. Our focus extends beyond creating

The importance of sharing knowledge for innovation Read More »

How well do you know your synthetic process?

Innovate / lara.james

Unreported changes to synthetic processes lead to the surprise presence of nitrosamine impurities in marketed drug products. This discovery resulted in the recall of several hypertension, heartburn, and diabetes medications. The nitrosamines crisis While many impurities are introduced directly as reagents, potentially mutagenic impurities (PMIs) arising during manufacture can be harder to identify as they

How well do you know your synthetic process? Read More »

What does the EMA update on nitrosamine impurities mean for you?

Discuss, Innovate / lara.james

Revised guidance released by the European Medicines Agency (EMA) on 7th July sparked excitement within the scientific community. By unveiling a new system to classify nitrosamines, EMA demonstrates that regulators are supporting industry in solving the complex problem of nitrosamine impurity assessment. The new approach will benefit industry, regulators and ultimately patients. What exactly are the

What does the EMA update on nitrosamine impurities mean for you? Read More »

Uniting with the Leeds tech sector to help young women discover careers in digital

Life at Lhasa / lara.james

We recently attended GirlTechLeeds, to help inspire the next generation of women in Tech! At Lhasa, we believe that it is important to create an environment where everyone can succeed, which is why our amazing colleagues volunteered their time to attend the event and share their knowledge and experience of working in a tech role. On

Uniting with the Leeds tech sector to help young women discover careers in digital Read More »

Establishing best practice for impurity purge by solubility

Innovate / lara.james

We are delighted to share our vital new article ‘Establishing best practice for the application and support of solubility purge factors’ which was recently published in Organic Process Research & Development (OPRD). The paper has been written by Lhasa Principal Scientist Michael Burns, alongside industry expert co-authors from AstraZeneca, GSK, Hoffman LaRoche and other forward

Establishing best practice for impurity purge by solubility Read More »

Author name: lara.james

10 FAQs About Mirabilis: Pharmaceutical Impurity Control Using In Silico Tools

Did you miss our webinar on degradation chemistry and nitrosamine risk assessment? Here are 5 top takeaways!

Have you read this? Benchmarking In silico prediction of pharmaceutical degradation pathways

Safeguarding Pharmaceutical Development: The Importance of Early Risk Mitigation

The importance of sharing knowledge for innovation

How well do you know your synthetic process?

What does the EMA update on nitrosamine impurities mean for you?

Uniting with the Leeds tech sector to help young women discover careers in digital

Establishing best practice for impurity purge by solubility

Sign up to our newsletter

Connect with us